GlassScriptPhysician profile
Renanda Stevenson
NPI 1366687113
$1,277.76
in general payments reported to CMS, 2019-2025
21 companies · $69.30 in 2025
The $69.30 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $373 · 2023: $273 · 2024: $299 · 2025: $69.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.28 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $218.62 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boston Scientific Corporation | $110.64 | 2024 | |
| Lilly USA, LLC | $87.93 | 2021-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $85.56 | 2022-2023 | Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $77.77 | 2022 | |
| Organon LLC | $70.17 | 2021-2022 | |
| Exact Sciences Corporation | $56.60 | 2023-2025 | Cologuard Collection Kit |
| Si-Bone, INC. | $47.85 | 2021-2024 | |
| Tactile Systems Technology INC | $46.69 | 2021-2023 | Entre Plus, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.14 | 2022 | |
| Optos, INC. | $35.68 | 2021 | |
| Gilead Sciences, INC. | $29.49 | 2023 | |
| Abbott Laboratories | $26.53 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $23.82 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2024 | Rexulti |
| Astellas Pharma US INC | $14.11 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2024 | |
| Pfizer INC. | $13.48 | 2023 | |
| Cequr Corporation | $6.51 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renanda Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.